Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
rhuMAb IFNalpha · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| rhuMAb IFNalpha | DRUG | Intravenous repeating dose |
Inclusion Criteria: * For patients with reproductive potential (males and females), use of a reliable means of contraception (e.g., hormonal contraceptive, patch, vaginal ring, intrauterine device, physical barrier) throughout their participation in the study * Diagnosis of SLE according to current...
Top 20 of 32 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Biogen Inc. | BIIB | 5 | PHASE3 | Litifilimab |
| Bristol-Myers Squibb Company | BMY | 7 | PHASE3 | Deucravacitinib |
| Viatris, Inc. | VTRS | 5 | PHASE3 | Cenerimod |
| Novartis AG Sponsored ADR | NVS | 7 | PHASE3 | Ianalumab |
| AstraZeneca PLC | AZN | 21 | PHASE3 | Medi-546 |
| Johnson & Johnson | JNJ | 1 | PHASE3 | Nipocalimab |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Upadacitinib |
| GSK plc Sponsored ADR | GSK | 3 | PHASE2 | Belimumab |
| Sanofi SA Sponsored ADR | SNY | 2 | PHASE2 | SAR441344 |
| Zenas BioPharma, Inc. | ZBIO | 1 | PHASE2 | Obexelimab |
| Alumis Inc. | ALMS | 1 | PHASE2 | Envudeucitinib |
| Immunovant Inc | IMVT | 1 | PHASE2 | IMVT-1402 |
| Amgen Inc. | AMGN | 1 | PHASE2 | Inebilizumab, Blinatumomab |
| Fate Therapeutics, Inc. | FATE | 2 | PHASE2 | FT819 |
| Eli Lilly and Company | LLY | 1 | PHASE1 | LY4298445 |
| Cartesian Therapeutics, Inc. | RNAC | 2 | PHASE2 | Descartes-08 |
| Merck & Co., Inc. | MRK | 1 | PHASE1 | MK-1045 |
| Gilead Sciences, Inc. | GILD | 1 | PHASE1 | KITE-363, Fludarabine, Cyclophosphamide |
| Artiva Biotherapeutics, Inc. | ARTV | 2 | PHASE1 | AB-101, Cyclophosphamide, Fludarabine, Rituximab, Obinutuzumab |
| Cullinan Therapeutics, Inc. | CGEM | 1 | PHASE1 | CLN-978 |
rhuMAb IFNalpha is an investigational drug being studied for the treatment of Systemic Lupus Erythematosus (SLE). It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being evaluated in adult patients with SLE.
rhuMAb IFNalpha is being developed by Roche Holding AG, a multinational healthcare company. Roche's stock is traded under the ticker symbol RHHBY. The drug is currently in Phase 1 clinical trials for Systemic Lupus Erythematosus.
rhuMAb IFNalpha is in Phase 1 clinical development. It is an investigational drug and has not yet been approved by regulatory agencies. The drug is being studied for the treatment of Systemic Lupus Erythematosus in adult patients.
rhuMAb IFNalpha has one completed Phase 1 clinical trial registered under NCT00541749. This study, titled 'A Study of rhuMAb IFNalpha in Adults With Systemic Lupus Erythematosus,' enrolled 60 participants. The trial was randomized and double-blind, though it did not use a control group.
rhuMAb IFNalpha is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for Systemic Lupus Erythematosus. The drug has completed one Phase 1 trial, but it remains in the early stages of clinical testing.